tiprankstipranks
Trending News
More News >
NanoCarrier Co., Ltd. (JP:4571)
:4571
Advertisement

NanoCarrier Co., Ltd. (4571) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4571

NanoCarrier Co., Ltd.

(Frankfurt:4571)

Rating:40Underperform
Price Target:
NanoCarrier Co., Ltd. faces significant financial challenges, with declining revenues and negative cash flows. While the company's balance sheet shows a strong equity position, operational and profitability issues are concerning. Technical analysis indicates a bearish trend, and the negative P/E ratio reflects ongoing financial struggles. These factors result in a low overall stock score, reflecting the company's current difficulties and uncertain outlook.

NanoCarrier Co., Ltd. (4571) vs. iShares MSCI Japan ETF (EWJ)

NanoCarrier Co., Ltd. Business Overview & Revenue Model

Company DescriptionNanoCarrier Co., Ltd. is a Japanese biopharmaceutical company that specializes in the development and commercialization of innovative nanotechnology-based drug delivery systems. The company focuses on creating highly effective and targeted treatments for cancer and other severe diseases through its proprietary micellar nanoparticle technology. NanoCarrier is committed to advancing healthcare by improving the efficacy and safety profiles of therapeutic agents.
How the Company Makes MoneyNanoCarrier Co., Ltd. generates revenue primarily through the development, licensing, and commercialization of its proprietary drug delivery systems. The company collaborates with pharmaceutical companies to co-develop drugs using its nanotechnology platforms, earning revenues from licensing fees, milestone payments, and royalties on sales of co-developed products. Additionally, NanoCarrier may receive funding from government grants or private investments to support its research and development activities. Strategic partnerships and collaborations with other biotech and pharmaceutical companies also play a significant role in enhancing its market reach and financial performance.

NanoCarrier Co., Ltd. Financial Statement Overview

Summary
NanoCarrier Co., Ltd. is experiencing financial difficulties with declining revenues and substantial operational losses. Despite a strong equity position and conservative debt management, the persistent lack of profitability and negative cash flows raise concerns about its long-term financial sustainability.
Income Statement
20
Very Negative
NanoCarrier Co., Ltd. has been experiencing declining revenue over the years, with the TTM (Trailing-Twelve-Months) revenue dropping significantly from previous periods. The company has negative profit margins, indicating it is not profitable. Both EBIT and EBITDA margins are deeply negative, reflecting operational challenges.
Balance Sheet
55
Neutral
The balance sheet shows a relatively strong equity position, with a low debt-to-equity ratio, indicating conservative leverage. However, the company's equity is decreasing over time. The equity ratio is solid, suggesting a strong reliance on equity financing, which is positive in managing financial risk.
Cash Flow
30
Negative
Cash flow analysis reveals significant challenges, with consistently negative free cash flow indicating cash outflows exceeding inflows. The company has not generated positive operating cash flow recently, which could threaten liquidity if this continues.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue108.52M135.51M202.19M264.03M313.26M
Gross Profit78.17M110.96M159.60M222.74M274.89M
EBITDA-832.57M-863.00M-1.30B-2.06B-1.30B
Net Income-835.38M-780.00M-1.31B-1.88B-2.84B
Balance Sheet
Total Assets4.00B5.07B5.78B7.14B7.82B
Cash, Cash Equivalents and Short-Term Investments3.51B4.28B4.44B5.95B6.40B
Total Debt540.24M1.11B1.11B1.15B0.00
Total Liabilities1.26B1.65B1.53B1.57B321.00M
Stockholders Equity2.74B3.42B4.25B5.57B7.50B
Cash Flow
Free Cash Flow0.00-585.08M-1.09B-1.76B-1.25B
Operating Cash Flow-401.62M-585.08M-1.09B-1.75B-1.25B
Investing Cash Flow587.53M793.01M1.21B-244.13M-871.69M
Financing Cash Flow-568.77M3.73M32.20M1.15B-11.46M

NanoCarrier Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price135.00
Price Trends
50DMA
134.80
Positive
100DMA
136.79
Positive
200DMA
147.21
Negative
Market Momentum
MACD
0.07
Positive
RSI
49.20
Neutral
STOCH
24.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Neutral. The current price of 135 is below the 20-day moving average (MA) of 138.05, above the 50-day MA of 134.80, and below the 200-day MA of 147.21, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 49.20 is Neutral, neither overbought nor oversold. The STOCH value of 24.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4571.

NanoCarrier Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$2.24T12.4512.99%2.25%0.73%7.75%
68
Neutral
$6.83T23.3717.60%1.65%17.77%49.34%
68
Neutral
¥34.94B18.34
4.52%8.07%-45.20%
65
Neutral
¥355.44B11.10-2.99%2.49%11.76%-10.16%
55
Neutral
¥13.08B
57.13%-66.39%
51
Neutral
¥8.29B
-56.12%-73.82%
40
Underperform
¥9.75B-26.97%-30.46%39.41%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4571
NanoCarrier Co., Ltd.
135.00
-57.00
-29.69%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,150.00
33.40
2.99%
JP:4579
RaQualia Pharma Inc.
535.00
-122.00
-18.57%
JP:4582
Symbio Pharmaceuticals Limited
160.00
-143.00
-47.19%
JP:4507
Shionogi & Co
2,554.00
361.99
16.51%
JP:4568
Daiichi Sankyo Company
3,630.00
-1,948.16
-34.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025